Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895671 | 0.88 | PPARA (0.40) | CASRPPARARORCRAB9ANPC1 | |
| SCHEMBL17895705 | 0.85 | RORC (0.39) | PPARARORCRAB9ANPC1CYP1A2 | |
| SCHEMBL17895712 | 0.85 | CYP3A4 (0.45) | PPARARORCRAB9ANPC1CYP1A2 | |
| SCHEMBL17895558 | 0.83 | RORC (0.37) | PPARARORCRAB9ANPC1CYP1A2 | |
| SCHEMBL17895693 | 0.82 | PPARA (0.38) | PPARARORCRAB9ANPC1CYP1A2 | |
| SCHEMBL17895643 | 0.81 | CASR (0.43) | CASRPPARARORCRAB9ANPC1 | |
| SCHEMBL17895611 | 0.76 | PIK3CA (0.39) | PPARARORCRAB9ANPC1CYP1A2 | |
| SCHEMBL17895605 | 0.75 | CYP3A4 (0.45) | CASRPPARARORCCYP3A4DYRK1A | |
| SCHEMBL7873642 | 0.74 | PPARA (0.51) | PPARARAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL8240791 | 0.73 | CYP19A1 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | claimed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | claimed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | claimed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | claimed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | claimed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CASR 2204/4885PPARA 437/4885RORC 326/4885 |
| US-11434234-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CASR 1902/4885PPARA 361/4885RORC 421/4885 |
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CASR 1902/4885PPARA 361/4885RORC 421/4885 |
| US-10287282-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CASR 2204/4885PPARA 437/4885RORC 326/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CASR 1902/4885PPARA 361/4885RORC 421/4885 |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CASR 1902/4885PPARA 361/4885RORC 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.